C. Kruse

发表

Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists.

J. Lange, C. Kruse, 2005, Drug discovery today.

Target-drug interactions: first principles and their application to drug discovery.

Jennifer Venhorst, J. Venhorst, C. Kruse, 2012, Drug discovery today.

Behavioural changes after different stress paradigms: prepulse inhibition increased after physical, but not emotional stress

J. M. Ree, C. Kruse, Femke TA Buisman-Pijlman, 2003, European Neuropsychopharmacology.

Analysis of Gene Expression in Parkinson's Disease: Possible Involvement of Neurotrophic Support and Axon Guidance in Dopaminergic Cell Death

C. Kruse, D. Swaab, J. Verhaagen, 2009, Brain pathology.

Modulation of midbrain dopamine neurotransmission by serotonin, a versatile interaction between neurotransmitters and significance for antipsychotic drug action.

C. Kruse, W. Wadman, A. McCreary, 2006, Current neuropharmacology.

Neurotensin attenuates the quinpirole-induced inhibition of the firing rate of dopamine neurons in the rat substantia nigra pars compacta and the ventral tegmental area

C. Kruse, W. Wadman, T. Werkman, 1999, Neuroscience.

Allosteric Inhibition of the Neuropeptidase Neurolysin*

Paul N. Mortenson, J. Lange, C. Kruse, 2014, The Journal of Biological Chemistry.

19th biennial IPEG Meeting

Asbjørn Mohr Drewes, Vitoantonio Bevilacqua, Roshan Cools, 2016 .

Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists.

J. Lange, C. Kruse, E. Ronken, 2002, Chemical & pharmaceutical bulletin.

Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives.

J. Lange, C. Kruse, 2008, Chemical record.

Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.

J. Glennon, J. Lange, C. Kruse, 2007, Journal of medicinal chemistry.

Cannabinoid antagonist SLV326 induces convulsive seizures and changes in the interictal EEG in rats

C. Kruse, C. V. van Rijn, G. van Luijtelaar, 2017, PloS one.

Activation of type-1 cannabinoid receptor shifts the balance between excitation and inhibition towards excitation in layer II/III pyramidal neurons of the rat prelimbic cortex

P. Chameau, T. Vitalis, C. Kruse, 2015, Pflügers Archiv - European Journal of Physiology.

Quetiapine increases the firing rate of rat substantia nigra and ventral tegmental area dopamine neurons in vitro.

C. Kruse, W. Wadman, Benny Perlstein, 2004, European journal of pharmacology.

Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.

J. Lange, C. Kruse, W. Wadman, 2011, European journal of medicinal chemistry.

7-Azaindole derivatives as potential partial nicotinic agonists.

C. Kruse, J. Reinders, A. Stoit, 2008, Bioorganic & medicinal chemistry letters.

Efficient library synthesis of imidazoles using a multicomponent reaction and microwave irradiation

R. Leurs, C. Kruse, R. Orru, 2006, Molecular Diversity.

Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists.

J. Lange, C. Kruse, A. McCreary, 2005, Journal of medicinal chemistry.

Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism.

J. Lange, C. Kruse, H. Coolen, 2010, Journal of medicinal chemistry.

Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists.

J. Lange, C. Kruse, E. Ronken, 2004, Journal of medicinal chemistry.

Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB(1) receptor antagonists.

J. Lange, C. Kruse, Herman H van Stuivenberg, 2010, Bioorganic & medicinal chemistry letters.

Microwave-enhanced Goldberg reaction: a novel route to N-arylpiperazinones and N-arylpiperazinediones

J. Lange, C. Kruse, R. Feenstra, 2002 .

N4-unsubstituted N1-arylpiperazines as high-affinity 5-HT1A receptor ligands.

A. IJzerman, C. Kruse, W. Kuipers, 1995, Journal of Medicinal Chemistry.

A novel atom-efficient, one-pot synthesis of sulfonylguanidines and sulfamoylguanidines

J. Lange, C. Kruse, Stefan Verhoog, 2011 .

SLV313 (1-(2,3-Dihydro-Benzo[1,4]Dioxin-5-yl)-4- [5-(4-Fluoro-Phenyl)-Pyridin-3-ylmethyl]-Piperazine Monohydrochloride): A Novel Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist Potential Antipsychotic Drug

J. Glennon, H. Meltzer, C. Kruse, 2007, Neuropsychopharmacology.

NK3 receptors mediate an increase in firing rate of midbrain dopamine neurons of the rat and the guinea pig

C. Kruse, W. Wadman, A. McCreary, 2011, Synapse.

Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors

P. Chameau, C. Kruse, W. Wadman, 2012, Proceedings of the National Academy of Sciences.

Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease.

C. Kruse, D. Swaab, J. Verhaagen, 2010, Brain : a journal of neurology.

Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum.

H. Wikström, B. Westerink, C. Kruse, 2001, European journal of pharmacology.

Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain.

B. Westerink, C. Kruse, P. de Boer, 1998, European journal of pharmacology.

Biophysical and physicochemical methods differentiate highly ligand-efficient human D-amino acid oxidase inhibitors.

Chris Oostenbrink, Natalia Markova, Jennifer Venhorst, 2011, European journal of medicinal chemistry.

Neonatal lesions in the amygdala or ventral hippocampus disrupt prepulse inhibition of the acoustic startle response; implications for an animal model of neurodevelopmental disorders like schizophrenia

J. M. Ree, C. Kruse, G. Wolterink, 2003, European Neuropsychopharmacology.

5-HT1A-versus D2-receptor selectivity of flesinoxan and analogous N4-substituted N1-arylpiperazines.

N. Veldman, A. Spek, A. IJzerman, 1997, Journal of medicinal chemistry.

New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D(2)-receptor and serotonin 5-HT(1A)-receptor affinities.

C. Kruse, W. Kuipers, M. Tulp, 2001, Bioorganic & medicinal chemistry letters.

Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia.

K. Marquis, S. Grauer, J. Brennan, 2009, Bioorganic & medicinal chemistry letters.

Highly Selective, Reversible Inhibitor Identified by Comparative Chemoproteomics Modulates Diacylglycerol Lipase Activity in Neurons.

P. Chameau, H. Overkleeft, T. Hankemeier, 2015, Journal of the American Chemical Society.

Endocannabinoids produced upon action potential firing evoke a Cl− current via type-2 cannabinoid receptors in the medial prefrontal cortex

P. Chameau, C. Kruse, W. Wadman, 2014, Pflügers Archiv - European Journal of Physiology.

Synthesis and SAR of 1,4,5,6-tetrahydropyridazines as potent cannabinoid CB1 receptor antagonists.

J. Lange, C. Kruse, Martina A W van der Neut, 2009, Bioorganic & medicinal chemistry letters.

Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity.

J. Lange, C. Kruse, A. McCreary, 2005, Bioorganic & medicinal chemistry letters.

Neonatal basolateral amygdala lesions affect monoamine and cannabinoid brain systems in adult rats.

H. Westenberg, C. Kruse, H. Bouwmeester, 2007, The international journal of neuropsychopharmacology.

WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: A Novel Dopamine D2 Receptor Partial Agonist/Serotonin Reuptake Inhibitor with Preclinical Antipsychotic-Like and Antidepressant-Like Activity

K. Marquis, S. Grauer, J. Brennan, 2010, Journal of Pharmacology and Experimental Therapeutics.

Assessment of scaffold hopping efficiency by use of molecular interaction fingerprints.

Chris G. Kruse, Jennifer Venhorst, J. Venhorst, 2008, Journal of medicinal chemistry.

In vitro modulation of the firing rate of dopamine neurons in the rat substantia nigra pars compacta and the ventral tegmental area by antipsychotic drugs

C. Kruse, W. Wadman, T. Werkman, 2001, Neuropharmacology.

5-HT2 receptors differentially modulate dopamine-mediated auto-inhibition in A9 and A10 midbrain areas of the rat

C. Kruse, W. Wadman, A. McCreary, 2004, Neuropharmacology.

5-HT6 Receptor Antagonists: Potential Efficacy for the Treatment of Cognitive Impairment in Schizophrenia.

C. Kruse, N. de Bruin, 2015, Current pharmaceutical design.

SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition.

C. Kruse, M. Hesselink, A. McCreary, 2003, Bioorganic & medicinal chemistry letters.

Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4-carboxamides by fine-tuning their 5-substitution pattern.

J. Lange, C. Kruse, Herman H van Stuivenberg, 2010, Bioorganic & medicinal chemistry letters.

Early amygdala damage in the rat as a model for neurodevelopmental psychopathological disorders

J. M. Ree, C. Kruse, G. Wolterink, 2001, European Neuropsychopharmacology.

Adaptation and habituation to an open field and responses to various stressful events in animals with neonatal lesions in the amygdala or ventral hippocampus

J. M. Ree, C. Kruse, G. Wolterink, 2001, Brain Research.

A straightforward synthetic approach for roxindole.

G. M. Visser, J. Lange, C. Kruse, 1999, Bioorganic & medicinal chemistry letters.

Spiro-1-benzofuranpiperidinylalkanoic acids as a novel and selective sphingosine S1P5 receptor agonist chemotype.

J. Lange, C. Kruse, A. Stoit, 2017, Bioorganic & medicinal chemistry letters.

DU 127090: a highly potent, atypical dopamine receptor ligand — a putative potent full spectrum antipsychotic with low EPS potential

C. Kruse, J. Mos, R. Feenstra, 2000, European Neuropsychopharmacology.

DU 127090: a highly potent, atypical dopamine receptor ligand — high potency but low efficacy at dopamine D2 receptors in vitro

C. Kruse, E. Ronken, M. Tulp, 2000, European Neuropsychopharmacology.

Novel 3,4‐Diarylpyrazolines as Potent Cannabinoid CB1 Receptor Antagonists with Lower Lipophilicity.

J. Lange, C. Kruse, A. McCreary, 2006 .

Assessment of a Novel Scoring Method Based on Solvent Accessible Surface Area Descriptors

Jennifer Venhorst, Sara Núñez, Chris G. Kruse, 2010, J. Chem. Inf. Model..

Effects of neonatal amygdala lesions on [125I] neurotensin binding in specific brain areas of adult rat

C. Kruse, H. Bouwmeester, E. Ronken, 2003, The European journal of neuroscience.

Endocannabinoids produced upon action potential firing evoke a Cl− current via type-2 cannabinoid receptors in the medial prefrontal cortex

P. Chameau, C. Kruse, W. Wadman, 2014, Pflügers Archiv - European Journal of Physiology.

Optimization of N'-(arylsulfonyl)pyrazoline-1-carboxamidines by exploiting a novel interaction site in the 5-HT6 antagonistic binding pocket.

J. Venhorst, J. Lange, C. Kruse, 2016, Bioorganic & medicinal chemistry letters.

Target-drug interactions: first principles and their application to drug discovery.

J. Venhorst, C. Kruse, S. Núñez, 2012, Drug discovery today.

Synthesis, Structure−Activity Relationships, and Biological Properties of 1-Heteroaryl-4-[ω-(1H-indol-3-yl)alkyl]piperazines, Novel Potential Antipsychotics Combining Potent Dopamine D2 Receptor Antagonism with Potent Serotonin Reuptake Inhibition

C. Kruse, A. Herremans, M. Hesselink, 2005 .

Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives.

J. Lange, C. Kruse, 2008, Chemical record.

Recent advances in CB1 cannabinoid receptor antagonists.

J. Lange, C. Kruse, 2004, Current opinion in drug discovery & development.

Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors

P. Chameau, C. Kruse, W. Wadman, 2012, Proceedings of the National Academy of Sciences.

Amygdala or ventral hippocampal lesions at two early stages of life differentially affect prepulse inhibition of the acoustic startle response; an animal model of a neurodevelopmental disorder like schizophrenia

J. M. Ree, C. Kruse, G. Wolterink, 2000, European Neuropsychopharmacology.